2022: The Year in Cardiovascular Disease – The Year of Upfront Lipid Lowering Combination Therapy.
Maciej Banach, Željko Reiner, Arrigo F.G. Cicero, Pierre Sabouret, Margus Viigimaa, Amirhossein Sahebkar, Arman Postadzhiyan, Dan Gaiță, Daniel Pella, Peter E. Penson
Abstract
Recent data clearly show that we are extremely ineffective in the use of lipid-lowering therapy (LLT). Furthermore, the problem seems to be the most serious in the group of patients at very high and extremely high-risk – the patients who stand to benefit most from effective therapy.
Topics & Concepts
MedicineDiseaseInternal medicineCoronary heart diseaseIntracerebral hemorrhageCardiologySubarachnoid hemorrhageLipoproteins and Cardiovascular HealthAntiplatelet Therapy and Cardiovascular DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins